LNSR
LENSAR, Inc. NASDAQ Listed Oct 2, 2020$5.75
+1.59%
vs $5.66
Mkt Cap $69.6M
52w Low $5.06
8.2% of range
52w High $13.47
50d MA $5.70
200d MA $9.73
P/E (TTM)
2.3x
EV/EBITDA
1.5x
P/B
—
Debt/Equity
-0.1x
ROE
131.8%
P/FCF
-4.5x
RSI (14)
49.70
ATR (14)
$0.29
Beta
0.98
50d MA
$5.70
200d MA
$9.73
Avg Volume
54.5K
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
2800 Discovery Drive · Orlando, FL 32826 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.07 | -0.12 | -80.7% | 5.96 | +5.5% | +0.2% | +1.5% | -2.8% | -4.4% | -1.8% | — |
| Nov 6, 2025 | AMC | -0.10 | -0.31 | -210.0% | 11.44 | +0.0% | -7.3% | -4.1% | +2.8% | -0.4% | -1.5% | — |
| Aug 7, 2025 | AMC | -0.08 | -0.15 | -87.5% | 12.84 | -0.4% | +0.2% | +1.2% | -0.8% | -1.2% | -2.0% | — |
| May 8, 2025 | AMC | -0.15 | -2.32 | -1446.7% | 13.81 | +0.1% | +0.8% | +0.2% | +0.3% | +1.4% | -0.4% | — |
| Feb 27, 2025 | AMC | -0.18 | -1.61 | -794.4% | 10.87 | +0.8% | +19.6% | +3.7% | +3.8% | +9.6% | -10.9% | — |
| Nov 7, 2024 | AMC | -0.29 | -0.13 | +55.2% | 6.87 | -1.2% | +7.4% | +0.0% | -4.6% | +5.0% | -2.6% | — |
| Aug 8, 2024 | AMC | -0.29 | -0.53 | -82.8% | 3.99 | -5.8% | +0.8% | +5.2% | -3.1% | -2.2% | +1.2% | — |
| May 9, 2024 | AMC | -0.28 | -0.19 | +32.1% | 3.82 | +0.8% | -1.0% | +1.3% | +3.7% | +4.5% | +0.2% | — |
| Mar 4, 2024 | AMC | -0.22 | -0.35 | -59.1% | 4.83 | +3.3% | -11.0% | +1.2% | -0.2% | -5.8% | +1.0% | — |
| Nov 9, 2023 | AMC | -0.34 | -0.23 | +32.4% | 2.26 | -2.7% | +0.4% | -4.8% | +2.8% | -5.0% | -0.7% | — |
| Aug 9, 2023 | AMC | -0.35 | -0.81 | -131.4% | 3.72 | -3.8% | -0.8% | -2.4% | -1.4% | -1.3% | -0.4% | — |
| May 15, 2023 | AMC | -0.27 | -0.40 | -48.1% | 2.30 | +3.9% | +0.4% | +2.6% | +11.4% | -4.9% | +12.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 | BTIG | Upgrade | Neutral → Buy | — | $6.89 | $7.26 | +5.4% | -4.5% | -7.1% | -3.3% | +2.7% | -8.4% |
| Mar 24 | Lake Street | Downgrade | Buy → Hold | — | $14.82 | $14.25 | -3.8% | -3.9% | -0.5% | -0.2% | +0.0% | -0.1% |
| Feb 28 | Lake Street | Maintains | Buy → Buy | — | $10.87 | $10.96 | +0.8% | +19.6% | +3.7% | +3.8% | +9.6% | -10.9% |
| Nov 22 | BTIG | Maintains | Buy → Buy | — | $7.10 | $7.25 | +2.1% | +2.1% | -3.0% | +1.3% | -1.5% | -1.4% |
| Feb 24 | SVB Leerink | Maintains | Outperform → Outperform | — | $9.50 | $9.51 | +0.1% | +0.6% | -5.3% | -0.1% | -1.3% | -1.7% |
No insider trades available.
8-K · 5.02
!!! Very High
LENSAR, Inc. -- 8-K 5.02: Executive Change
May 29
8-K · 2.02
!! High
LENSAR, Inc. -- 8-K 2.02: Earnings Results
LENSAR's earnings results press release has been filed with the SEC, though the specific financial metrics and performance outcomes are not detailed in this summary and must be reviewed in the attached exhibit.
May 8
8-K
Tenax Therapeutics, Inc. -- 8-K Filing
Tenax Therapeutics' CFO previously led Triangle Pharmaceuticals through its acquisition by Gilead Sciences, demonstrating experience navigating pharma M&A transactions that could benefit Tenax shareholders.
Apr 22
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
LNSR's executive departure signals potential leadership instability and operational uncertainty, which could pressure the stock unless management quickly names a qualified successor.
Apr 15
8-K
Unknown — 8-K Filing
LENSAR's failed acquisition deal forces independent strategy pivot, potentially delaying growth plans but offering opportunity for standalone value creation if execution improves.
Mar 31
8-K · 1.02
!! High
Unknown — 8-K 1.02: Material Agreement Terminated
Lineser's merger deal collapsed, eliminating expected synergies and strategic growth plans, likely pressuring the stock as investors reassess the company's standalone future and potential strategic alternatives.
Mar 17
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Lannister is clarifying previously disclosed PCL Agreement terms, suggesting potential ambiguity that required official correction—investors should monitor for material changes to deal conditions or financial impact.
Mar 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
I cannot provide a meaningful analysis because the filing summary is incomplete and contains only boilerplate language without disclosing the actual material event, making it impossible to assess financial impact.
Mar 12
8-K · 7.01
! Medium
LENSAR, Inc. -- 8-K 7.01: Regulation FD Disclosure
LENSAR announced an acquisition status update from Alcon Research, LLC, providing investors with new information regarding the pending deal's progress and timeline.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 390,090 | $2M | New | Mar 2026 |
| 2 | Groupe La Francaise | 213,537 | $1M | Added | Mar 2026 |
| 3 | Credit Industriel Et Commercial | 144,359 | $860K | Added | Mar 2026 |
| 4 | Morgan Stanley | 61,844 | $719K | Added | Dec 2025 |
| 5 | Rbf Capital, Llc | 91,054 | $543K | — | Mar 2026 |
| 6 | Strs Ohio | 43,500 | $506K | — | Dec 2025 |
| 7 | Yakira Capital Management, Inc. | 83,288 | $496K | Reduced | Mar 2026 |
| 8 | Ubs Group Ag | 83,272 | $496K | Added | Mar 2026 |
| 9 | Man Group Plc | 75,056 | $447K | New | Mar 2026 |
| 10 | Northern Trust Corp | 66,130 | $394K | — | Mar 2026 |
| 11 | Deltec Asset Management Llc | 32,500 | $378K | — | Dec 2025 |
| 12 | Rangeley Capital, Llc | 63,000 | $375K | Added | Mar 2026 |
| 13 | Vanguard Portfolio Management Llc | 56,793 | $338K | New | Mar 2026 |
| 14 | Centiva Capital, Lp | 46,200 | $275K | Reduced | Mar 2026 |
| 15 | Jane Street Group, Llc | 20,818 | $242K | Added | Dec 2025 |
| 16 | Nuveen, Llc | 30,061 | $179K | — | Mar 2026 |
| 17 | Essex Investment Management Co Llc | 30,034 | $179K | — | Mar 2026 |
| 18 | Bank Of New York Mellon Corp | 22,179 | $132K | Reduced | Mar 2026 |
| 19 | Royal Bank Of Canada | 20,095 | $120K | Added | Mar 2026 |
| 20 | Millennium Management | 12,565 | $75K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$69.6M
Enterprise Value
$49.7M
P/E (TTM)
2.30x
Forward P/E
—
PEG Ratio
-0.79x
P/B
—
P/S
1.19x
P/FCF
-4.54x
EV/EBITDA
1.46x
Shares Out
12.0M
Financials (TTM)
Revenue
$57.7M
Net Income
$29.4M
EBITDA
$34.0M
Free Cash Flow
-$14.9M
Op Cash Flow
-$14.8M
EPS Basic
$-2.87
EPS Diluted
$-0.58
EPS Forward
$-0.30
Gross Margin
45.3%
Op Margin
-28.7%
Net Margin
50.9%
Balance Sheet
Total Assets
$71.4M
Total Liab.
$97.4M
Total Equity
-$26.0M
Cash
$18.0M
LT Debt
$0
Book Value/Sh
$-2.18
Debt/Equity
-0.11x
Current Ratio
1.15
Quick Ratio
0.62
Returns & Growth
ROE
131.8%
ROA
-48.0%
ROIC
-77.8%
Rev Growth YoY
+9.2%
EPS Growth YoY
-5.1%
Price Returns
2W
-0.5%
1M
+10.9%
3M
-51.5%
6M
-43.0%
12M
-57.1%
Technicals
52W High
$13.47
52W Low
$5.06
50d MA
$5.70
200d MA
$9.73
RSI (14)
49.70
ATR (14)
$0.29
Beta
0.98
Avg Volume
54K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$10.00
High
$10.00
Low
$10.00
Median
$10.00
Data updated apr 25, 2026 7:32pm
· Source: financialmodelingprep.com